Enteris BioPharma to Participate in the American Association of Pharmaceutical Scientists (AAPS) 2021 PHARMSCI 360 Conference
- S&P 500, Dow hit new highs with heavy week of earnings on tap
- Tesla (TSLA) Joins Apple, Amazon, Microsoft, Google in Trillion Dollar Club
- PayPal (PYPL) Stock Soars Over 6% on Confirmation It Won't Acquire Pinterest (PINS) 'At This Time'; PINS Stock Down 11%
- Biggest Single EV Purchase Ever: Tesla (TSLA) Stock Soars as Hertz Orders 100,000 EVs in $4.2 Billion Deal, Analyst Bulled-up
- Oil prices reach multi-year highs on tight supply
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
BOONTON, N.J., Oct. 13, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that the company will participate in the American Association of Pharmaceutical Scientists (AAPS) 2021 PHARMSCI 360 Conference taking place October 17-20, 2021 at the Pennsylvania Convention Center in Philadelphia. This year's meeting includes both in-person and virtual attendance options.
During the conference, members of the Enteris management team will host virtual and in-person meetings with pharmaceutical executives to explore opportunities involving Peptelligence® and ProPerma®, the company's novel formulation technologies that enable oral delivery of BCS class III and IV compounds including peptides, peptidomimetics, small molecules, as well as the company's recently launched contract development and manufacturing operations (CDMO) and expanded manufacturing facility. Enteris continues to advance internal and external programs that leverage Peptelligence and ProPerma, some of which are in late-stage clinical development.
Rajiv Khosla, Ph.D., Chief Executive Officer of Enteris, stated, "Since launching our CDMO operations and completing our expanded manufacturing facility earlier this year, we have had the opportunity to engage numerous pharmaceutical companies that require our highly specialized drug development and manufacturing services, including high potency API (HPAPI) containment production. We believe these capabilities, combined with our best-in-class Peptelligence and ProPerma technologies, position Enteris as a partner-of-choice to pharmaceutical companies, and we welcome the opportunity to showcase our offerings during AAPS."
About Enteris BioPharmaEnteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated contract development and manufacturing (CDMO) services including innovative formulation solutions utilizing its proprietary drug delivery technologies, Peptelligence® and ProPerma™. The technologies have been the subject of numerous feasibility studies and active development programs, several of which are in clinical development. Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of drug products that address significant unmet clinical needs for which there is no satisfactory treatment option. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit www.EnterisBioPharma.com.
View original content:https://www.prnewswire.com/news-releases/enteris-biopharma-to-participate-in-the-american-association-of-pharmaceutical-scientists-aaps-2021-pharmsci-360-conference-301399113.html
SOURCE Enteris BioPharma, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RISE Consortium elevates Defense TechConnect Summit, awards Innovation Challenge winners
- STXfilms Partners On Writer Director Lori Evans Taylor's "Bed Rest" Starring Melissa Barrera From Project X Entertainment
- Cleanfarms Collecting Unwanted Agricultural Pesticides and Old Livestock/Equine Medications in New Brunswick November 1 to 12
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!